Product Information
VANCOMYCIN HCL 250 MG CAPSULE is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $1.9925 per EA under NDC 68180016713. Its NADAC has been published 540 times since Apr 29, 2015.
FDA first approved this application on Jan 28, 2015.
Strength
250 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180016713
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
VANCOMYCIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090439FDA Approved
1/28/2015
On Market Since
3/27/2015
Pharmacological Classes
Price Statistics
The NADAC for VANCOMYCIN HCL 250 MG CAPSULE has been published 540 times since Apr 29, 2015, and over the history we have for it it has declined 88.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9925 per EA |
|---|---|
| All-time high | $19.6789 (Jun 10, 2015) |
| All-time low | $1.4284 (Nov 20, 2024) |
| Median price | $4.2712 |
| Average price | $6.2199 |
| Largest weekly change | +51.3% (Jan 19, 2022) |
| Weeks tracked | 540 |
| Tracking since | Apr 29, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-14.9%
5Y
-34.5%
All
-88.1%
Last surveyed Aug 27, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the VANCOMYCIN HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
VANCOMYCIN HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Glycopeptide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VANCOMYCIN HCL 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VANCOMYCIN HCL 250 MG CAPSULE, manufactured by Lupin Pharmaceuticals Inc., is $1.9925 per EA (NDC 68180016713), effective Aug 27, 2025.
How has the price of VANCOMYCIN HCL 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VANCOMYCIN HCL 250 MG CAPSULE has declined 88.1%. It has been tracked across 540 weekly CMS publications since Apr 29, 2015.
What are the highest and lowest recorded NADAC prices for VANCOMYCIN HCL 250 MG CAPSULE?
Since Apr 29, 2015, the NADAC for VANCOMYCIN HCL 250 MG CAPSULE has ranged from a low of $1.4284 (Nov 20, 2024) to a high of $19.6789 (Jun 10, 2015), with a median of $4.2712 per EA.
Are there cheaper alternatives to VANCOMYCIN HCL 250 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of VANCOMYCIN HCL 250 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VANCOMYCIN HCL 250 MG CAPSULE?
VANCOMYCIN HCL 250 MG CAPSULE (NDC 68180016713) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.